Roivant Sciences Ltd.

ROIVSEC EDGAR

Pharmaceutical Preparations(D0)CIK: 1635088

Concept	FY2024	FY2023	FY2022
Revenue from Contract with Customer, Excluding Assessed Tax	$31.5M	$61.3M	$23.8M
Research and Development Expense	$454.1M	$525.2M	$236.6M
Selling, General and Administrative Expense	—	$600.5M	—
Operating Expenses	$938.3M	$1.2B	$1.1B
Operating Income (Loss)	-$906.8M	-$1.2B	-$1.1B
Interest Expense	—	$28.0M	$2.8M
Other Nonoperating Income (Expense)	-$486.0K	$15.8M	-$8.7M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$885.0M	-$1.2B	-$898.5M
Income Tax Expense (Benefit)	$4.1M	$5.2M	$1.7M
Net Income (Loss) Attributable to Parent	-$1.0B	-$1.0B	-$809.2M

Concept	FY2024	FY2023	FY2022
Assets	$7.2B	$2.4B	$2.6B
Assets, Current	$6.7B	$1.8B	$2.2B
Cash and Cash Equivalents, at Carrying Value	$6.5B	$1.7B	$2.1B
Inventory, Net	—	$2.8M	—
Liabilities	$774.0M	$782.0M	$527.7M
Liabilities, Current	$266.8M	$272.4M	$219.0M
Long-term Debt	—	$375.5M	$170.3M
Accounts Payable, Current	$14.0M	$37.8M	$20.6M
Stockholders' Equity Attributable to Parent	$6.0B	$1.2B	$1.8B
Common Stock, Shares, Outstanding	$806.7M	$760.1M	$651.6M

Concept	FY2024	FY2023	FY2022
Net Cash Provided by (Used in) Operating Activities	-$843.4M	-$843.4M	-$552.1M
Net Cash Provided by (Used in) Investing Activities	-$44.3M	-$44.3M	-$31.7M
Net Cash Provided by (Used in) Financing Activities	$499.5M	$499.5M	$456.3M
Payments to Acquire Property, Plant, and Equipment	$12.7M	$12.7M	$5.8M
Payments for Repurchase of Common Stock	$0.00	—	—

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)